Ching-Hsun Wang1, Feng-Yee Chang1, Tsu-Yi Chao2, Woei-Yau Kao3, Ching-Liang Ho4, Yeu-Chin Chen4, Ming-Shen Dai4, Ping-Ying Chang4, Yi-Ying Wu4, Jung-Chung Lin5. 1. Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 2. Department of Hematology Oncology, Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare, Taipei, Taiwan. 3. Division of Hematology Oncology, Department of Internal Medicine, Taipei Tzu Chi General Hospital, Taipei, Taiwan. 4. Division of Hematology Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 5. Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Electronic address: linjungchung1@yahoo.com.tw.
Abstract
BACKGROUND: The aim of this study was to compare the risk factors and clinical outcomes of bacteremia in allogeneic and autologous hematopoietic stem cell transplant (allo-HSCT and auto-HSCT) recipients with levofloxacin prophylaxis during the early period after transplantation. METHODS: Characteristics of bacteremia within 45 days after transplantation between allo-HSCT and auto-HSCT recipients who received levofloxacin prophylaxis between January 2005 and December 2014 were retrospectively reviewed. RESULTS: Of 105 HSCT recipients included in this study, 55 (52.4%) received an allo-HSCT and 50 (47.6%) received an auto-HSCT. Twenty-five patients (23.8%) with HSCT developed 28 episodes of bacteremia. Of these 25 bacteremia patients, 15 received an allo-HSCT, while 10 received an auto-HSCT. The occurrence of Grade 3-4 graft-versus-host disease and longer engraftment duration were associated with bacteremia in allo- and auto-HSCT recipients (p = 0.001 and p = 0.002, respectively). Auto-HSCT recipients with bacteremia had a longer hospital stay after transplantation, while allo-HSCT recipients with bacteremia had an increased 45-day mortality rate as compared with those without bacteremia (p = 0.014 and p = 0.013, respectively). All 14 Gram-negative blood isolates in this study were resistant to fluoroquinolone. CONCLUSION: Levofloxacin prophylaxis in HSCT recipients is associated with the emergence of fluoroquinolone-resistant Gram-negative bacteria. The risk factors and clinical outcomes of bacteremia differ between allo- and auto-HSCT recipients, and these differences should be taken into account when designing strategies to prevent bacteremia.
BACKGROUND: The aim of this study was to compare the risk factors and clinical outcomes of bacteremia in allogeneic and autologous hematopoietic stem cell transplant (allo-HSCT and auto-HSCT) recipients with levofloxacin prophylaxis during the early period after transplantation. METHODS: Characteristics of bacteremia within 45 days after transplantation between allo-HSCT and auto-HSCT recipients who received levofloxacin prophylaxis between January 2005 and December 2014 were retrospectively reviewed. RESULTS: Of 105 HSCT recipients included in this study, 55 (52.4%) received an allo-HSCT and 50 (47.6%) received an auto-HSCT. Twenty-five patients (23.8%) with HSCT developed 28 episodes of bacteremia. Of these 25 bacteremiapatients, 15 received an allo-HSCT, while 10 received an auto-HSCT. The occurrence of Grade 3-4 graft-versus-host disease and longer engraftment duration were associated with bacteremia in allo- and auto-HSCT recipients (p = 0.001 and p = 0.002, respectively). Auto-HSCT recipients with bacteremia had a longer hospital stay after transplantation, while allo-HSCT recipients with bacteremia had an increased 45-day mortality rate as compared with those without bacteremia (p = 0.014 and p = 0.013, respectively). All 14 Gram-negative blood isolates in this study were resistant to fluoroquinolone. CONCLUSION:Levofloxacin prophylaxis in HSCT recipients is associated with the emergence of fluoroquinolone-resistant Gram-negative bacteria. The risk factors and clinical outcomes of bacteremia differ between allo- and auto-HSCT recipients, and these differences should be taken into account when designing strategies to prevent bacteremia.
Authors: Joyce Ji; Jeff Klaus; Jason P Burnham; Andrew Michelson; Colleen A McEvoy; Marin H Kollef; Patrick G Lyons Journal: Chest Date: 2020-06-17 Impact factor: 9.410
Authors: Matthew Ziegler; Daniel Landsburg; David Pegues; Warren Bilker; Cheryl Gilmar; Colleen Kucharczuk; Theresa Gorman; Kristen Bink; Amy Moore; Rebecca Fitzpatrick; Edward A Stadtmauer; Patricia Mangan; Kelly Kraus; Jennifer H Han Journal: Biol Blood Marrow Transplant Date: 2018-11-24 Impact factor: 5.742
Authors: Giana Berleze Penna; Tassiana Costa da Silva; Alessandra Aparecida Paz; Bruna Ziegler Journal: Support Care Cancer Date: 2021-01-04 Impact factor: 3.359
Authors: Natalia Ptaszyńska; Katarzyna Gucwa; Katarzyna Olkiewicz; Mateusz Heldt; Marcin Serocki; Anna Stupak; Dorota Martynow; Dawid Dębowski; Agata Gitlin-Domagalska; Jan Lica; Anna Łęgowska; Sławomir Milewski; Krzysztof Rolka Journal: Int J Mol Sci Date: 2020-06-30 Impact factor: 5.923
Authors: Celalettin Ustun; Jo-Anne H Young; Genovefa A Papanicolaou; Soyoung Kim; Kwang Woo Ahn; Min Chen; Hisham Abdel-Azim; Mahmoud Aljurf; Amer Beitinjaneh; Valerie Brown; Jan Cerny; Saurabh Chhabra; Mohamed A Kharfan-Dabaja; Parastoo B Dahi; Andrew Daly; Christopher E Dandoy; Christopher C Dvorak; Cesar O Freytes; Shahrukh Hashmi; Hillard Lazarus; Per Ljungman; Taiga Nishihori; Kristin Page; Sai R K Pingali; Ayman Saad; Bipin N Savani; Daniel Weisdorf; Kirsten Williams; Baldeep Wirk; Jeffery J Auletta; Caroline A Lindemans; Krishna Komanduri; Marcie Riches Journal: Bone Marrow Transplant Date: 2018-12-13 Impact factor: 5.483